Epizyme (EPZM) Tops Q4 EPS by 19c

Epizyme (NASDAQ: EPZM) reported Q4 EPS of ($0.29), $0.19 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $8 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• BMO starts chip stocks coverage: Here are its preferred picks